3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Carcinoma, Non-Small-Cell Lung
14
Lung Neoplasms
6
Triple Negative Breast Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
3
Pancreatic Neoplasms
3
Colorectal Neoplasms
3
Urinary Bladder Neoplasms
2
Carcinoma, Renal Cell
2
Uveal Melanoma
1
Squamous Non-small Cell Lung Cancer
1
Small Cell Lung Carcinoma
1
Primary Myelofibrosis
1
Polycythemia Vera
1
Oropharyngeal Neoplasms
1
Neoplasm, Residual
1
Neoplasm Metastasis
1
Nasopharyngeal Carcinoma
1
Microsatellite Instability
1
Melanoma
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Large B-Cell, Diffuse
1
Liver Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Breast Cancer Female
1
Biliary Tract Neoplasms
1
Adenocarcinoma of Lung
1
Adenocarcinoma Of Esophagus
1
Interventions
trametinib
2
olaparib
1
glembatumumab vedotin
1
durvalumab
1
cediranib
1
Vorinostat
1
Nivolumab
1
Magnetic Resonance Spectroscopy
1
Ipilimumab
1
CTLA-4 Antigen
1
CR011-vcMMAE
1
Biopsy, Fine-Needle
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
Uveal Melanoma
×
durvalumab
×
Clear all
NCT04184518
2020-06-02
CEDUVEAL-M
Grupo Español Multidisciplinar de Melanoma
Phase 2
Withdrawn